GlaxoSmithKline Uses Clinical Graphics Solution Developed by Insightful Corporation
News Apr 30, 2008
Insightful Corporation has announced that GlaxoSmithKline (GSK) is using a clinical graphics solution developed by Insightful and S-PLUS®, Insightful’s software platform for statistical data analysis and predictive analytics, to speed the design, analysis, and reporting of clinical trial data.
"We are committed to this S-PLUS graphics solution to assist our statisticians and scientists in understanding our data, and to improve the communication of results," said Dr. Roger F. Liddle, Vice President of Discovery Biometrics at GSK and sponsor of GSK’s clinical graphics initiative.
“As of end of 2007, we have over 200 statisticians, programmers and epidemiologists trained. We are seeing significant uptake of the S-PLUS graphics solution, with the majority of users finding it an easy way to produce high quality graphs. The clinical graphics our staff are producing are being used by GSK statisticians, clinicians, and publishing staff in several critical areas, including data analysis, presentation, submission, and publication,” Liddle added.
Insightful’s clinical graphics solutions are designed to enable effective communication of clinical data in journals, presentations, and regulatory submissions through point-and-click creation of advanced graphics and seamless integration with existing exploratory, presentation, and production reporting environments.
Important benefits of these clinical graphics solutions include the ease of use for those without specialized programming skills and streamlined graphics production across all clinical and reporting areas, minimizing the time and cost incurred by expensive and scarce statistical programming resources.
GSK is employing Insightful’s S-PLUS platform and advanced statistical graphics libraries, including Trellis™ technology and a comprehensive graphics taxonomy collection. These libraries deliver industry-standard graphics for interpreting and communicating information in clinical data.
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019